At the end of summer we told you all about a new initiative of the National Brain Tumor Society called the Clinical Trial Endpoints Initiative. At the time we were just getting back from an extremely fruitful meeting with the U.S. Food & Drug Administration (FDA), which set the stage for two upcoming workshops with [...]
National Brain Tumor Society hosted the inaugural Advancing Research to Therapies (ART) for Brain Tumors Conference in Washington, D.C. during Brain Tumor Awareness Month in May, 2013. The ART Conference brought together more than 100 leading experts from academic research labs, government agencies, biotech and pharmaceutical companies, and venture capital firms
National Brain Tumor Society staff and advisors recently met with the U.S. Food and Drug Administration (FDA) to discuss how various stakeholders in brain tumor drug development could work together to increase the volume and speed of approvals for new treatments for this disease.